CRBU
Caribou Biosciences, Inc.
$2.36
+2.16%
2026-05-29
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Key Fundamentals
Forward P/E
-1.26
EPS (TTM)
$-1.59
ROE
-79.0%
Revenue Growth (YoY)
89.7%
Profit Margin
0.0%
Debt/Equity
22.29
Price/Book
1.48
Beta
2.27
Market Cap
$187.0M
Avg Volume (10D)
1.3M
Recent Breakout Signals
No recent breakout signals detected for CRBU.
Recent Price Range (60 Days)
60D High
$2.40
60D Low
$1.66
Avg Volume
1.4M
Latest Close
$2.36
Get breakout alerts for CRBU
Sign up for Breakout Scanner to receive daily notifications when CRBU triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Caribou Biosciences, Inc. (CRBU) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CRBU daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CRBU operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.